Lantheus announces FDA approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection. Learn more.

Because we’re making headlines

Please visit our investor site for a complete list of recent and archived press releases, follow us on LinkedIn for social media updates and browse below for additional media resources.

Latest press releases

See all press releases

Press release

October 23, 2024

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Read more

Press release

September 15, 2024

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Read more

Additional resources

Media library

Images, videos and other assets bring news about Lantheus to life.

Events

Events allow us to connect with our people, patients and partners.

Investors

All investor resources can be found on our dedicated investor website.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com